Skip to content

US · PGNY · MEDICAL - HEALTHCARE INFORMATION SERVICES

Progyny, Inc. (PGNY) intrinsic value and stock valuation

$35.71as of 2026-11-21 · Mkt cap 2.46B

Data updated · price as of 2026-11-21

Fairly valuedIC value is within 20% of the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Progyny, Inc. DCF and intrinsic value

InvestorsCraft values PGNY with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from PGNY’s statements →

Progyny, Inc. Graham Number

Graham Number: $9.67d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Healthcare Information Services New York City, NY 10018 progyny.com

How the business is doing

Fiscal 2017–2025, USD

Revenue
$1.29B+30.2% 5y CAGRd
20172025
Net income
$58.5M+4.7% 5y CAGRd
20172025
Free cash flow
$191.8M+40.4% 5y CAGRd
20172025
Total equity
$516M+25.3% 5y CAGRd
20172025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2017–2025, USD
20252024202320222021
Revenue$1.29B$1.17B$1.09B$786.9M$500.6M
Operating income$85.3M$67.5M$62.2M$23.3M$32.3M
Net income$58.5M$54.3M$62M$30.4M$65.8M
EPSd$654.1K$569.3K$616.3K$303.7K$655.3K
Operating cash flow$210.2M$179.1M$188.8M$80.4M$26M
Capital expenditure-$-18.41M-$-5.41M-$-3.64M-$-3.24M-$-2.13M
Free cash flow$191.8M$173.7M$185.2M$77.2M$23.9M
Total assets$742.4M$607.1M$756.6M$543M$358.1M
Total debt$27.7M$19.3M$19.4M$7.71M$8.65M
Net debt-$-84.51M-$-143.04M-$-77.91M-$-112.36M-$-82.76M
Total equity$516M$422.1M$553.4M$377M$251.8M
Cash and short-term investments$310.1M$228M$371.1M$189.3M$119.4M
Income statement
20252024202320222021
Revenue$1.29B$1.17B$1.09B$786.9M$500.6M
Cost of revenue$984.2M$913.9M$849.8M$619.6M$388.5M
Gross profit$304.5M$253.4M$238.8M$167.3M$112.1M
Research and development expenses$0.00$0.00$0.00$0.00$0.00
Selling, general and administrative expenses$219.2M$185.9M$176.6M$144M$79.8M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$219.2M$185.9M$176.6M$144M$79.8M
Cost and expenses$1.2B$1.1B$1.03B$763.6M$468.3M
Interest income$10.2M$15.8M$8.51M$810K$460K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$4.95M$3.17M$2.28M$1.6M$1.3M
Ebitda$100.4M$86.4M$73M$26M$33.7M
Operating income$85.3M$67.5M$62.2M$23.3M$32.3M
Total other income/expenses, net$10.2M$15.8M$8.51M$1.1M$100K
Income before tax$95.4M$83.2M$70.7M$24.4M$32.4M
Income tax expense$36.9M$28.9M$8.65M-$-5.92M-$-33.33M
Net income$58.5M$54.3M$62M$30.4M$65.8M
Weighted average shares outstanding$85.2M$91.5M$95M$92.2M$89.1M
Weighted average diluted shares outstanding$89.5M$95.5M$100.7M$100M$100.4M
Balance sheet
20252024202320222021
Cash and short-term investments$310.1M$228M$371.1M$189.3M$119.4M
Net receivables$220.3M$235.3M$241.9M$240.1M$134.6M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$551.8M$472.7M$640.4M$433.9M$258.5M
Property, plant and equipment, net$54.9M$29.6M$27.8M$15.3M$12.8M
Goodwill and intangible assets$26.2M$16.8M$11.9M$12M$12.5M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$190.7M$134.4M$116.2M$109.1M$99.5M
Total assets$742.4M$607.1M$756.6M$543M$358.1M
Accounts payable$124.1M$95.1M$125.4M$109.3M$61.4M
Short-term debt$3.73M$2.86M$2.15M$1.23M$1.23M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$202.4M$168.6M$186M$159.5M$98.8M
Long-term debt$24M$16.4M$17.2M$6.48M$7.42M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$24M$16.4M$17.2M$6.48M$7.42M
Capital lease obligations$27.7M$19.3M$19.4M$7.71M$8.65M
Total liabilities$226.4M$185M$203.2M$166M$106.2M
Common stock$10K$10K$10K$10K$10K
Retained earnings$202.8M$144.3M$90M$27.9M-$-2.42M
Accumulated other comprehensive income (loss)$500K$40K$2.82M$500K-$-90K
Total equity$516M$422.1M$553.4M$377M$251.8M
Total investments$197.9M$65.6M$273.8M$69.2M$28M
Total debt$27.7M$19.3M$19.4M$7.71M$8.65M
Net debt-$-84.51M-$-143.04M-$-77.91M-$-112.36M-$-82.76M
Cash flow statement
20252024202320222021
Net income$58.5M$54.3M$62M$30.4M$65.8M
Depreciation and amortization$4.95M$3.17M$2.28M$1.6M$1.3M
Stock-based compensation$131.9M$128.1M$122.6M$100.8M$33.7M
Change in working capital$2.8M-$-11.78M-$-17.42M-$-59.49M-$-51.26M
Accounts receivable-$-5.12M-$-9.87M-$-21.74M-$-119.3M-$-68.68M
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$28.8M-$-30.27M$16.2M$47.7M$17.8M
Net cash provided by operating activities$210.2M$179.1M$188.8M$80.4M$26M
Investments in property, plant and equipment-$-18.41M-$-5.41M-$-3.64M-$-3.24M-$-2.13M
Acquisitions, net-$-9.34M-$-5.3M$0.00$0.00$0.00
Net cash used for investing activities-$-159.01M$195.8M-$-200.53M-$-43.87M$8.77M
Common stock issued$1.23M$2.4M$6.13M$4.22M$4.27M
Common stock repurchased-$-81.66M-$-300.28M$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-99.36M-$-309.88M-$-11.07M-$-7.86M-$-13.7M
Net change in cash-$-48.12M$65M-$-22.78M$28.7M$21.1M
Cash at end of period$114.2M$162.3M$97.3M$120.1M$91.4M
Operating cash flow$210.2M$179.1M$188.8M$80.4M$26M
Capital expenditure-$-18.41M-$-5.41M-$-3.64M-$-3.24M-$-2.13M
Free cash flow$191.8M$173.7M$185.2M$77.2M$23.9M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Progyny, Inc.

        Progyny, Inc. functions as a benefits management corporation, dedicated to providing specialized solutions for fertility and broader family-building initiatives to employers throughout the United States. Its core fertility offering is characterized by a distinctive benefits plan architecture, paired with personalized, white-glove member support services and access to a meticulously chosen network of top-tier fertility specialists. Additionally, the company presents Progyny Rx, an all-encompassing pharmacy benefits solution that ensures its members can readily acquire the essential medications for their treatments. Moreover, Progyny facilitates employer-sponsored reimbursement programs to support surrogacy and adoption journeys. The company, which was established in 2008 and has its main offices in New York City, previously operated as Auxogyn, Inc. before adopting the Progyny, Inc. moniker in 2015.

        CEO
        Pete Anevski
        Employees
        856
        Beta
        1.02

        Explore

        Frequently asked questions

        What is the intrinsic value of Progyny, Inc. (PGNY)?

        Progyny, Inc. (PGNY) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is PGNY undervalued?

        PGNY trades at a price of $35.71 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.